translocations or amplifications on top of the genomic alterations already existing in the first CLL, but absence the frequent mutations observed in Main DLBCL indicating that they may correspond to another Organic class.gene in patients relapsing right after cure Along with the BCL2 antagonist venetoclax. sixty six Resistance to those agents conti